McKee Charlotte
Known title: CMO and Head of R&DCIK: 0002046433
Associated companies
Transaction History
| SION | ▲ Buy | Grant | 50,000 | $0 | 9/17/2026 | View on chart |
| SION | ▲ Buy | Grant | 50,000 | $0 | 9/17/2026 | View on chart |
| SION | ▲ Buy | Grant | 50,000 | $0 | 9/17/2026 | View on chart |
| SION | ▲ Buy | Grant | 50,000 | $0 | 9/17/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible
Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.
Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible. Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.